Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

J&J teams up with Orexo for respiratory drug development; terminated

Executive Summary

Orexo (working on therapeutics for pain and inflammatory conditions) has licensed Johnson & Johnson's Ortho-McNeil Janssen Pharmaceuticals Inc. and Janssen Pharmaceutica NV (collectively OMJ) global rights to its OX-CLI and OX-ESI preclinical programs for asthma, COPD, and other inflammatory diseases. OMJ will also add a third internal drug candidate to the three-year-deal.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Co-Promotion
    • R&D and Marketing (Licensing)

Related Companies